ALK Inhibitor Response in Melanomas Expressing EML4-ALK sorted by
relevance

Admin20.07.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

95010
Admin14.07.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

Admin08.10.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

4903
Admin21.08.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

Admin24.07.2021

(PDF) ALK inhibitor response in melanomas expressing EML4

900
Admin04.09.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

3104
Admin24.08.2021

Effects of ALK inhibition in the EML4-ALK-positive NSCLC

Admin08.08.2021

ALK inhibitor sensitivity of EML4-ALK variants. A, Ba/F3

6706
Admin21.07.2021

Combined inhibition of ALK and MEK enhances response and

9704
Admin25.09.2021

The ALK mutation L1152R causes the ALK tyrosine kinase

72010
Admin31.07.2021

ALK inhibitor sensitivity of EML4-ALK variants. A, Ba/F3

1104
Admin23.07.2021

The combination of ALK and PLX4032 inhibitors is efficient

8608
Admin03.08.2021

Combined inhibition of ALK and MEK enhances response and

4205
Admin27.09.2021

ALK inhibitor sensitivity of EML4-ALK variants. A, Ba/F3

7702
Admin15.08.2021

ALK inhibitor sensitivity and protein stability of KIF5b

2602
Admin21.07.2021

Cancers | Free Full-Text | Mechanisms of Acquired

6008
Admin21.08.2021

FDA approved ALK inhibitors with substantial impact in the

7400
Admin06.10.2021

ATCC - The Generation of an EML4-ALK Fusion NSCLC Isogenic

6307
Admin05.09.2021

EML4-ALK (E13;A20, variant 1) lung adenocarcinoma cells

606
Admin07.09.2021

Intracellular distribution of EML4-ALK variants and

3805
Admin15.07.2021

Frontiers | A Systemic Review of Resistance Mechanisms and

7506